eCysticFibrosis Review

Individuals with cystic fibrosis — adults as well infants and children — have long struggled to gain and maintain their weight. But how has the current widespread use of highly effective modulator treatments — HEMT — changed that situation? That's the focus of this eCysticFibrosis Review Special Edition: CF and Nutrition and HEMT.  The first part of this program presented an evidence-based Expert Commentary on the current status of weight gain, obesity, and nutrition among people with CF by guest author Katie McDonald, PhD, MS, RDN, CSP, a clinical dietitian at Primary Children's Medical Center in Salt Lake City. The second part is a podcast interview, providing further in-depth discussions between Katie McDonald and three top CF nutrition experts.  Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit? Join us as we explore these questions with guest author Professor Edward McKone MD, from St. Vincent's University Hospital and University College Dublin School of Medicine, in this eCysticFibrosis Review podcast. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Managing pulmonary exacerbations in people with cystic fibrosis: is there high-grade evidence to support best practices? How helpful is the most current guidance? Does the recent research challenge the current standard of care? Join us for this eCysticFibrosis Review podcast, as Dr. D.B. Sanders from the Indiana University School of Medicine explains how these questions can affect clinical care. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Race and ethnicity. How do they affect a patient's ability to receive a timely and accurate cystic fibrosis diagnosis? How do the social determinants of health limit access to appropriate CF treatment and produce poorer outcomes? That's what we're here to talk about today with Dr. Jennifer Taylor-Cousar from National Jewish Health and Children's Hospital Colorado in this eCysticFibrosis Review podcast. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Pancreatic insufficiency. In children with CF, it's been associated with delayed development and increased odds of developing severe lung disease. How can it be more accurately diagnosed? And what does the evidence say about the effects of treatment with CFTR modulators?That's what we explore in this case-based podcast, with Dr. Vikesh Singh, Associate Professor of Medicine and Director of the Pancreatitis Center at Johns Hopkins Medical Institutions.  Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams' ability to effectively maintain their patients' health? What information out there is proved, what's speculation, and what is simply unknown? These questions are the focus of this eCysticFibrosis Review Special COVID Edition issue. Lisa Saiman MD, MPH, professor of pediatrics at Columbia University Irving Medical Center, analyzes the current literature investigating these questions and then speaks directly with front-line clinicians about what they're experiencing as they navigate a disrupted health care system. In addition to presenting her analysis of the data-driven evidence describing the effects of the COVID-19 virus on people with cystic fibrosis, Dr. Saiman also spoke directly with front-line CF clinicians to learn about what they've been experiencing as they work to maintain effective patient care. Transcripts of these interviews can be accessed throughout the newsletter.Take our post-test to claim CME credits. Hosted on Acast. See acast.com/privacy for more information.

Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams' ability to effectively maintain their patients' health? What information out there is proved, what's speculation, and what is simply unknown? These questions are the focus of this eCysticFibrosis Review Special COVID Edition issue. Hosted on Acast. See acast.com/privacy for more information.

Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams' ability to effectively maintain their patients' health? What information out there is proved, what's speculation, and what is simply unknown? These questions are the focus of this eCysticFibrosis Review Special COVID Edition issue. Hosted on Acast. See acast.com/privacy for more information.

Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams' ability to effectively maintain their patients' health? What information out there is proved, what's speculation, and what is simply unknown? These questions are the focus of this eCysticFibrosis Review Special COVID Edition issue. Hosted on Acast. See acast.com/privacy for more information.

Studies have shown that adolescent and young adult women with cystic fibrosis often turn to their CF care team for answers to their questions about their sexual and reproductive health. But how prepared are CF clinicians to initiate conversations? Do they have the most current data about pregnancy decisions for women taking CFTR modulators? When should modulator therapy be stopped? When is it safe to continue?In this eCysticFibrosis Review podcast, Dr. Traci Kazmerski from UPMC Children's Hospital of Pittsburgh and Dr. Natalie West from Johns Hopkins University take us into the clinic to address these important questions.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Airway infections are a hallmark of cystic fibrosis, making antibiotic therapies a mainstay of CF treatment. While the fight against ABX resistance is ongoing, newer data are showing that commonly used dosing regimens may have to be altered to account for the particular pharmacodynamics in people with CF. How should ABX dosing be altered, and what additional effect might CFTR modulation have on dosing decisions?That's the topic Dr. Andrea Hahn, Assistant Professor of Pediatrics and an Infectious Disease Specialist at Children's National Medical Center and George Washington University School of Medicine and Health Sciences, addresses in this eCysticFibrosis Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

No-contact telemedicine to better protect CF clinic patients and staff during this pandemic may sound like a great idea, but is it even possible to institute? In this eCysticFibrosis Review Special Edition podcast, we find out how pulmonary and critical care specialists Dr. Dana Albon and Dr. Lindsay Somerville successfully brought telemedicine to their Adult Cystic Fibrosis Clinic at University of Virginia Health.Take our post-test to claim CME credits. Hosted on Acast. See acast.com/privacy for more information.

Where, beyond the lungs, do CFTR modulators provide beneficial effects? Can treatment promote growth in height and BMI? What's known about CFTR modulator effects on cystic fibrosis-associated liver disease? In this eCysticFibrosis Review podcast, Drs. Darla Shores and Anna Reed from the THRIVE Pediatric Intestinal Rehabilitation Center in the Division of Gastroenterology, Hepatology, and Nutrition at the Johns Hopkins Children's Center take us to the clinic to answer these and other questions crucial to the health of our patients with cystic fibrosis.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Elexacaftor/tezacaftor/ivacaftor — the newly approved triple combination CFTR modulator therapy. What are the benefits? For which patients? What are the potential adverse effects? Who's most likely to receive them? In this issue, Dr. Scott Sagel from the Breathing Institute at the Children's Hospital Colorado, part of the University of Colorado's Anschutz Medical Campus, takes us to the clinic to discuss some answers.Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Anxiety and depression in cystic fibrosis — who do these conditions affect? How much do they influence patient health? How can clinicians identify and manage them? What evidence-based interventions have been shown to work?In this issue, Dr. Anna Georgiopoulos, Assistant Professor of Psychiatry, Part-Time, Harvard Medical School and Consulting Psychiatrist, Massachusetts General Hospital Cystic Fibrosis Program, takes us to the clinic to answer these questions that can be key to the health and well-being of children, adults, and families living with CF.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

New CFTR modulators for F508del mutations? New research into reducing inflammation in the CF lung? In this issue, Dr. Jennifer Taylor-Cousar from National Jewish Health in Denver explains the potential clinical impact of new and emerging CF disease modifying therapies.Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Inhaled antibiotics have become the foundation of treating chronic respiratory tract Pseudomonas infection in individuals with cystic fibrosis. But what happens when inhaled monotherapy doesn't sufficiently manage the symptoms? Which patients are appropriate candidates for treatment with multiple inhaled agents? Which medications are appropriate for continuous alternating therapy (CAT)?In this Issue, Dr. Elliott Dasenbrook from the Cleveland Clinic brings the evidence he analyzed in his recent eCysticFibrosis Review Newsletter issue (Vol 8; Issue 10) into the clinic to help guide clinical decision-making.Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

The effects of CFTR modifiers on improving lung function in people with cystic fibrosis are well known. But what about their effects on the GI tract that directly affect nutrition?In this issue, Dr. Michael Wilschanski — Director of Hadassah Hospital's Pediatric Gastroenterology Unit at Hebrew University in Jerusalem — explains how new findings about CFTR modification can impact clinical practice. Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Volume 8, Issue 7. Part 3 Hosted on Acast. See acast.com/privacy for more information.

Volume 8, Issue 7. Part 2 Hosted on Acast. See acast.com/privacy for more information.

Volume 8, Issue 7. Part 1 Hosted on Acast. See acast.com/privacy for more information.

In this issue, Dr. Gregory Sawicki — Associate Professor of Pediatrics at Harvard Medical School and Director of the Cystic Fibrosis Center at Boston Children's Hospital — discusses how the recent findings about the real-world use of CFTR modulators can impact clinical practice.Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Multidrug resistant lung infections present an increasingly common and increasingly dangerous threat to all individuals with cystic fibrosis. Common CF pathogens — Pseudomonas aeruginosa, Burkholderia cepacia complex, Achromobacter xylosoxidans, Stenotrophomonas maltophilia — are all showing increasing resistance to clinicians' usual antibiotic armamentarium.In this issue, Dr. Claire Elson, from the University of Missouri Kansas City School of Pharmacy, and Dr. Christopher Oermann, from the UMKC School of Medicine, describe strategies for the clinical management of these resistant infections.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Screening to avoid the morbidity and mortality of colorectal cancer (CRC) in patients with CF, with the incidence of CRC rising, has become an increasingly important challenge, particularly among lung transplant patients. But how and when should patients be screened? With colonoscopy or non-invasive FIT? Before or after transplant? Are there patients who should not be screened, and why?In this issue, Dr. Denis Hadjiliadis from the Perelman School of Medicine at the University of Pennsylvania discusses the clinical aspects of screening patients with CF to prevent CRC.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Volume 7, Issue 12.In this podcast Dr. John P. Clancy reviews CFTR modulators, and discusses insights presented at the 2017 NACFC.Take our post-test to claim CME credits:Physician post-testNurse post-testTo read a companion newsletter click here.The post CFTR Modulators: Clinical Insights appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 7, Issue 10.In this podcast Andrea Granados, MD describes the clinical impact of the early diagnosis of glucose abnormalities in people with CF, summarizes the limitations of alternative modalities for screening and diagnosing CFRD, and and identifies the current recommendations for the management of CFRD.Take our post-test to claim CME credits:Physician post-testNurse post-testTo read a companion newsletter click here.The post Screening and Diagnosis of CFRD appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 7, Issue 8.In this podcast Dr. George Solomon discusses new directions in CFTR modification in the context of case studies.Take our post-test to claim CME credits:Physician post-testNurse post-testTo read a companion newsletter click here.The post New Directions in CFTR Modification appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 7, Issue 6.Our guest author is Amanda Leonard, MPH, RD, CDE, from the Johns Hopkins Children's Hospital in Baltimore, MD.Take our post-test to claim CME credits:Physician post-testNurse post-testTo read a companion newsletter click here.The post Nutritional Management for Individuals with CF: Practical Applications appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 7, Issue 4.Our guest author is Gregory Sawicki, MD, MPH from Boston Children's Hospital, and Harvard Medical School in Boston, MA.Take our post-test to claim CME credits:Physician post-testNurse post-testTo read a companion newsletter click here.The post Adherence – What You Should be Telling Your Patients appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 7, Issue 2.Our guest authors are Mark T. Jennings, MD, MHS and Rebecca Dezube, MD from the Johns Hopkins University School of Medicine in Baltimore, MD.Take our post-test to claim CME credits:Physician post-testNurse post-testTo read a companion newsletter click here.The post Weighing the Options in Managing Exacerbations appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 6, Issue 12.Claire Wainwright, FRACP, MD and Tonia Douglas, MD cover the important topic of the Future Landscape of CFTR Modulators in the format of case-study scenarios for the clinical practice.Take our post-test to claim CME credits:Physician post-testNurse post-testTo read a companion newsletter click here.The post Future Landscape of CFTR Modulators appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 6, Issue 10.Christopher Oermann, MD covers the important topic of the Pseudomonas Eradication in the format of case-study scenarios for the clinical practice.Take our post-test to claim CME credits:Physician post-testNurse post-testTo read a companion newsletter click here.The post Pseudomonas aeruginosa Eradication and Outcomes: Key Questions appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 6, Issue 8.Dr. Deepak Agrawal, MD covers the important topic of Nutritional Issues in Cystic Fibrosis in the format of case-study scenarios for the clinical practice.Take our post-test to claim CME credits:Physician post-testNurse post-testTo read a companion newsletter click here.The post Nutritional Issues in Cystic Fibrosis appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 6, Issue 6.Daniel Heintz, MD and Karen McCoy, MD cover the important topic of Trends in Inhaled Antibiotic Therapy in the format of case-study scenarios for the clinical practice.Take our post-test to claim CME credits:Physician post-testNurse post-testTo read a companion newsletter click here.The post Trends in Inhaled Antibiotic Therapy appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 6, Issue 4.Our guest author is John J. LiPuma from the University of Michigan in Ann Arbor, Michigan.Take our post-test to claim CME credits:Physician post-testNurse post-testTo read a companion newsletter click here.The post Pulmonary Exacerbations and the Microbiology of the CF Lung appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 6, Issue 2.In this issue we are joined by one of our Program Directors, Dr. Noah Lechtzin from the Johns Hopkins University. Dr. Lechtzin will address the current state of CFTR modification and how it can be applied in practice.Take our post-test to claim CME credits:Physician post-testNurse post-testTo read a companion newsletter click here.The post The Current State of CFTR Modification appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Special Edition 2015, Part 4.Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. Stuart Elborn of Queen's University in Belfast, Ireland. Dr. Elborn discusses the implications of the CAT study and how it effects his practice.The post Breaking Coverage of CAT trial appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Special Edition 2015, Part 3.Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. JP Clancy of Cincinnati Children's Hospital. Dr. Clancy discusses the implications of the CAT study and how it effect his practice.The post Breaking Coverage of CAT trial appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Special Edition 2015, Part 2.Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. Scott Bell of the QIMR Berghofer Medical Research Institute. Dr. Bell discusses the implications of the CAT study and how it will effect his practice.The post Breaking Coverage of CAT trial appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Special Edition 2015, Part 1.Join us as Dr. Peter Mogayzel of the Johns Hopkins University discusses the design and findings for the CAT study with Dr. Patrick Flume of the Medical University of South Carolina. Learn about the importance of the study and how it may effect your practice.The post Breaking Coverage of CAT trial appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 5, Issue 14.In this issue we are joined by Dr. Shawn Aaron of University of Ottawa in Ontario, Canada. Dr. Aaron will discuss infection in patients with optimal therapy of chronic Pseudomonas aeruginosa cystic fibrosis, describe the pathophysiology of pulmonary exacerbations associated with Pseudomonas infection in patients with cystic fibrosis, and evaluate the optimal choice of antibiotics to treat Pseudomonas-associated pulmonary exacerbations in patients with cystic fibrosis.The post Agents for the management of Pseudomonas aeruginosa infection appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 5, Issue 12.In this issue of eCysticfibrosis Review Dr. Chris Goss of the University of Washington Medical Center. Dr. Goss discusses the benefits of CFTR modification beyond Fev1 improvement through the use of patient-cases.The post Benefits of CFTR Modification Beyond FEV1 Improvement appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 5, Issue 10.In this issue of eCystifibrosis Review we will be join by Dr. Stuart Elborn of Queens University in Belfast, Northern Ireland. Dr. Elborn discusses the effects of CFTR-Modifying Therapies. He will present three patient-case scenarios and identify appropriate treatment options.The post The Effects of CFTR-modifying Therapies appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 5, Issue 8.In this issue of eCysticFibrosis Review Dr. John Pohl discuses how to optimize nutrition in individuals with CF. Through patient case-scenarios he applies best practices to achieve optimal nutrition using PERT dosing.The post Optimizing Nutrition in Individuals with Cystic Fibrosis appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 5, Issue 6.In this issue Dr. Steven Freedman, Professor of Medicine from Harvard Medical School discusses digestive capabilities in nutritionally compromised patients with CF. Listen in as Dr. Freedman explains the importance of pancreatic enzyme replacement and present patient scenarios and best practices of treatment.The post Improving digestive capabilities in nutritionally compromised patients with CF appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 5, Issue 4.In this issue of eCysticfibrosis Review Dr. Ratjen discusses the challenges of P. aeruginosa eradication. He explains the importance to treat early and available treatment options. He also addresses whether treatment should be repeated in patients who develop recurrence of infection and how to handle patients failing eradication therapy.The post P. aeruginosa eradication and reinfection appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 5, Issue 2.In this podcast Dr. Patrick Flume, Professor of Medicine and Pediatrics at the Medical University of South Carolina in Charleston, discusses pulmonary exacerbation. He provides patient case scenarios to understand the importance of pulmonary exacerbation and the ability to identify when it occurs.The post Pulmonary exacerbations: diagnoses, and therapeutic regimens appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 4, Issue 12.In this issue our guest author is Dr. Patrick Sosnay, Assistant Professor at the Johns Hopkins Cystic Fibrosis Center. Dr. Sosnay will illustrate how the genetics of CF can be used to make a diagnosis or identify a CF carrier, predict how individuals with a given mutation will do clinically and allow clinicians to select currently available and hopefully future therapies that directly address the defect caused by their individual CFTR mutations.The post What Does CFTR Tell Us About Lung Disease? appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Volume 4, Issue 10.In this podcast we have guest author Lori Stark, PhD, ABPP, Professor of Pediatrics at the University of Cincinnati College of Medicine. Dr. Stark, discusses how to use “shaping” to encourage a child to eat a non-preferred food, describes the role of “attention” in maintaining behaviors incompatible with eating, and discusses the use of caloric goal-setting and dietary tracking applications to monitor treatment progress.The post Behavioral Treatment to Improve Dietary Adherence and Weight Gain in Children with Cystic Fibrosis appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Special Edition 2014 – Steven Rowe.In this special edition of eCysticFibrosis Review, Dr. Peter Mogayzel discusses data findings from Dr. Steven Rowe results of the G551D observational study presented at the 27th Annual North American Cystic Fibrosis Conference in Salt Lake City, Utah.The post Highlights of the 27th Annual North American Cystic Fibrosis Conference appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Special Edition 2014 – Steven Rowe.In this special edition of eCysticFibrosis Review, Dr. Peter Mogayzel discusses data findings from Dr. Steven Rowe results of the G551D observational study presented at the 27th Annual North American Cystic Fibrosis Conference in Salt Lake City, Utah.The post Highlights of the 27th Annual North American Cystic Fibrosis Conference appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.